Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries

  • Expanded partnership to help “even the odds” of survival for children with cancer in the Philippines, Myanmar, Mexico and Ghana
  • In developed countries, the survival rate for childhood cancer is 80%, while in developing countries it can be as low as 10%
  • Sandoz is committed to working with key stakeholders to pioneer novel ways of expanding access to healthcare

The digital press release with multimedia content can be accessed here: 

…

/by

Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products

  • Net sales in line with prior year (0% cc[1], -2% USD), as growth drivers offset Gleevec/Glivec Gx impact:
    • Cosentyx (USD 490 million, +90% cc) continues strong growth in all three indications
    • Entresto (USD 110 million) grew steadily driven by improved access and US sales force expansion
    • Excluding Gleevec/Glivec, Oncology grew 9% (cc), driven by Promacta, Tafinlar + Mekinist  and Jakavi
    • Sandoz declined 4% (cc) mainly impacted by increased US pricing pressure
    • Alcon grew 3% (cc) driven by Surgical (+3 …
/by